Sato et al. [169] demonstrated that peptides derived from SYT-SSX fusion genes, resultant from chromosomal translocation t(X:18) specific to synovial sarcoma (SS), are recognized by circulating CD8+ T-cells in HLA-A24+ patients, and induce tumor-specific cytotoxic responses. Here, CD8A is linked to synovial sarcoma.